Riley J Morrow
Overview
Explore the profile of Riley J Morrow including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
6
Citations
78
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Nightingale R, Reehorst C, Vukelic N, Papadopoulos N, Liao Y, Guleria S, et al.
Dev Cell
. 2024 May;
59(15):1988-2004.e11.
PMID: 38781975
The transcription factor EHF is highly expressed in the lactating mammary gland, but its role in mammary development and tumorigenesis is not fully understood. Utilizing a mouse model of Ehf...
2.
Morrow R, Ernst M, Poh A
STAR Protoc
. 2023 Feb;
4(1):102110.
PMID: 36853665
Tumor-derived organoids are valuable for testing anti-cancer drugs in vitro, but existing lysis-based protocols for viability measurement are laborious and restricted at a single time point. Here, we provide a...
3.
Morrow R, Allam A, Konecnik J, Baloyan D, Dijkstra C, Eissmann M, et al.
Cells
. 2022 Dec;
11(24).
PMID: 36552868
Aberrant expression of the oncoprotein c-Myc (Myc) is frequently observed in solid tumors and is associated with reduced overall survival. In addition to well-recognized cancer cell-intrinsic roles of Myc, studies...
4.
Morrow R, Allam A, Yeo B, Deb S, Murone C, Lim E, et al.
Cancers (Basel)
. 2022 May;
14(9).
PMID: 35565421
Inflammatory breast cancer (IBC) describes a highly aggressive form of breast cancer of diverse molecular subtypes and clonal heterogeneity across individual tumors. Accordingly, IBC is recognized by its clinical signs...
5.
Morrow R, Etemadi N, Yeo B, Ernst M
Mediators Inflamm
. 2017 Jun;
2017:4754827.
PMID: 28607534
Inflammatory breast cancer is a rare, yet highly aggressive form of breast cancer, which accounts for less than 5% of all locally advanced presentations. The clinical presentation of inflammatory breast...
6.
Coulson R, Liew S, Connelly A, Yee N, Deb S, Kumar B, et al.
Oncotarget
. 2017 Apr;
8(12):18640-18656.
PMID: 28416734
Drugs that target the Renin-Angiotensin System (RAS) have recently come into focus for their potential utility as cancer treatments. The use of Angiotensin Receptor Blockers (ARBs) and Angiotensin-Converting Enzyme (ACE)...